# A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Source: https://onco.cc/trials/nct06637423/  
OnCo record `nct06637423` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Sacituzumab tirumotecan in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) is a phase 1/2 interventional study registered as NCT06637423 by Merck Sharp & Dohme LLC, with 32 participants planned, started 2024-12-20 and due to reach its primary completion in 2029-03-14. Interventions recorded: Sacituzumab tirumotecan, Rescue medication and Supportive care measures.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06637423
- Phase: 1/2
- Setting: A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 32

## Sources

- ClinicalTrials.gov NCT06637423: https://clinicaltrials.gov/study/NCT06637423

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06637423.json